{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:49:28Z","timestamp":1785905368878,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019444","name":"Compass Therapeutics LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019444","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jad.2026.122063","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:15:14Z","timestamp":1780586114000},"page":"122063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression"],"prefix":"10.1016","volume":"412","author":[{"given":"Carlton M.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Fradet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bostian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ostacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Aaronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Suppes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.122063_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2026.122063_bb0015","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0020","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0025","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/jts.22975","article-title":"Minimal important difference metrics and test-retest reliability of the PTSD Checklist for DSM-5 with a primary care sample","volume":"36","author":"Blanchard","year":"2023","journal-title":"J. Trauma. Stress."},{"key":"10.1016\/j.jad.2026.122063_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41398-022-02285-2","article-title":"The complex clinical response to selective serotonin reuptake inhibitors in depression: a network perspective","volume":"13","author":"Boschloo","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0035","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2026.122063_bb0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2215-0366(25)00372-4","article-title":"Brief individual psychological intervention for people with probable personality disorder: a multicentre, researcher-masked, randomised, controlled superiority trial in England","volume":"13","author":"Crawford","year":"2026","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7249\/rhq-05-04-13","article-title":"Current and projected characteristics and unique health care needs of the patient population served by the Department of Veterans Affairs","volume":"5","author":"Eibner","year":"2016","journal-title":"Rand Health Q."},{"key":"10.1016\/j.jad.2026.122063_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.119655","article-title":"Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study","volume":"389","author":"Ellis","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122063_bb0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jad.2024.09.133","article-title":"Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - a first-in-kind open-label pilot study","volume":"369","author":"Ellis","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122063_bb0070","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2026.122063_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102799","article-title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial","volume":"76","author":"Erritzoe","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2026.122063_bb0080","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15465","article-title":"Prevalence, correlates, and burden of subthreshold PTSD in US veterans","volume":"85","author":"Fischer","year":"2024","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0085","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1017\/S1092852924002487","article-title":"Psilocybin and hallucinogenic mushrooms","volume":"29","author":"Fradet","year":"2024","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2026.122063_bb0090","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2026.122063_bb0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life","volume":"327","author":"Goodwin","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122063_bb0100","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15449","article-title":"Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder","volume":"86","author":"Goodwin","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0105","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3389\/fphar.2020.00559","article-title":"Comparative efficacy and acceptability of pharmaceutical management for adults with post-traumatic stress disorder: a systematic review and meta-analysis","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167901","article-title":"Early improvement in psychosocial function predicts longer-term symptomatic remission in depressed patients","volume":"11","author":"Jha","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2026.122063_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jad.2022.04.025","article-title":"The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression","volume":"308","author":"Jones","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122063_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jpsychires.2024.02.013","article-title":"Generalized anxiety and mild anxiety symptoms in U.S. military veterans: prevalence, characteristics, and functioning","volume":"171","author":"Macdonald-Gagnon","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122063_bb0140","series-title":"ACNP 63rd Annual Meeting","first-page":"T257","article-title":"An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes","author":"McGowan","year":"2024"},{"key":"10.1016\/j.jad.2026.122063_bb0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.psychres.2013.03.031","article-title":"Prevalence and features of generalized anxiety disorder in Department of Veteran Affairs primary care settings","volume":"209","author":"Milanak","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.122063_bb0150","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.jad.2026.122063_bb0155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamapsychiatry.2017.3379","article-title":"Effectiveness of online collaborative care for treating mood and anxiety disorders in primary care: a randomized clinical trial","volume":"75","author":"Rollman","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0160","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0165","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jad.2026.122063_bb0170","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0175","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jad.2026.122063_bb0180","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122063_bb0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpsychires.2016.06.022","article-title":"The association between post-traumatic stress disorder and lifetime DSM-5 psychiatric disorders among veterans: data from the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III)","volume":"82","author":"Smith","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122063_bb0190","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jad.2026.122063_bb0195","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jad.2020.01.032","article-title":"Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7)","volume":"265","author":"Toussaint","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122063_bb0200","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2026.122063_bb0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/wps.20943","article-title":"Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): III. Emotional dysfunction superspectrum","volume":"21","author":"Watson","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0210","series-title":"The PTSD Checklist for DSM-5 (PCL-5)","author":"Weathers","year":"2013"},{"key":"10.1016\/j.jad.2026.122063_bb0215","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11469-024-01253-9","article-title":"Unique psychological mechanisms underlying psilocybin therapy versus escitalopram treatment in the treatment of major depressive disorder","volume":"22","author":"Weiss","year":"2024","journal-title":"Int. J. Ment. Heal. Addict."},{"key":"10.1016\/j.jad.2026.122063_bb0220","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4088\/JCP.14m09328","article-title":"Posttraumatic stress disorder in the US veteran population: results from the National Health and Resilience in Veterans Study","volume":"75","author":"Wisco","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122063_bb0225","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1037\/rev0000589","article-title":"Common factors in altered states: understanding psychedelic therapy through the lens of Grawe\u2019s general change mechanisms","volume":"132","author":"Wolff","year":"2025","journal-title":"Psychol. Rev."},{"key":"10.1016\/j.jad.2026.122063_bb0230","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/YIC.0b013e32832d6bf4","article-title":"Assessing health-related quality of life in generalized anxiety disorder using the Quality of Life Enjoyment and Satisfaction Questionnaire","volume":"24","author":"Wyrwich","year":"2009","journal-title":"Int. Clin. Psychopharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726009158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726009158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:23:12Z","timestamp":1785903792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726009158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":46,"alternative-id":["S0165032726009158"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122063","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122063"}}